ATXI — Avenue Therapeutics Income Statement
0.000.00%
- $3.25m
- -$0.89m
- 10
- 30
- 51
- 21
Annual income statement for Avenue Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 26.3 | 5.21 | 3.74 | 8.04 | 14.5 |
Operating Profit | -26.3 | -5.21 | -3.74 | -8.04 | -14.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -25.9 | -5.15 | -3.73 | -3.6 | -10.5 |
Net Income After Taxes | -25.9 | -5.15 | -3.73 | -3.6 | -10.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -25.9 | -5.15 | -3.73 | -3.55 | -10.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -25.9 | -5.15 | -3.73 | -3.55 | -10.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,854 | -351 | -247 | -122 | -73.5 |